Source: International Congress 2019 – Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Mehlman (Boulogne-Billancourt, France), J. Cadranel (Paris, France), R. Lacave (Paris, France), G. Rousseau-Bussac (Creteil, France), A. Pujals (Creteil, France), N. Girard (Paris, France), I. Bieche (Paris, France), V. Gounant (Paris, France), N. Théou-Anton (Paris, France), S. Friard (Suresnes, France), J. Trédaniel (Paris, France), H. Blons (Paris, France), C. Dujon (Versailles, France), B. Duchemann (Bobigny, France), P. Schischmanoff (Bobigny, France), T. Chinet (Boulogne-Billancourt, France), E. Giroux Leprieur (Boulogne-Billancourt, France). Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer. 370

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018 The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient Source: Eur Respir J 2015; 46: 280-282 Year: 2015 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012 Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009